Wang Hui, Shen Luyan, Lin Yao, Shi Qi, Yang Yongbo, Chen Keneng
Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, P.R. China.
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C74-9. doi: 10.4103/0973-1482.163846.
Mucin 13 (MUC13) and Mucin 20 (MUC20) are high molecular weight transmembrane O-linked glycoprotein secreted by epithelium and are widely overexpressed in epithelial tumor cells. Previously, it has been reported that MUC13 and MUC20 were prognostic molecular biomarkers of some epithelial tumors, but few has studied the relations between MUC13 or MUC20 expression and the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Thus, the aim of our study was to explore this issue.
Immunohistochemistry was used to detect the expressions of MUC13 and MUC20 in 186 patients with ESCC who received neoadjuvant chemotherapy followed by surgery. We analyzed the correlations between MUC13 or MUC20 expression and long-term survival of these patients.
The expression of MUC13 and MUC20 in ESCC mainly occurred in the cytoplasm. Among the 186 subjects, 53.8% had high MUC13 expression and 38.2% had high MUC20 expression. Univariate analysis showed that neither MUC13 nor MUC20 was significantly associated with long-term survival. When combining expression of MUC13 with MUC20, we found that the median survival time of patients with low MUC13/high MUC20 expression was significantly shorter than that of patients with high MUC13/low MUC20 expression (27.7 months vs. 59.5 months, P = 0.021). Multivariate analysis showed that combination of MUC13/MUC20 expression was an independent prognostic factor (hazard ratios = 0.531, 95% confidence interval: 0.299-0.944, P = 0.031).
A combination of MUC13/MUC20 expression was a potential prognostic marker for patients with ESCC, who received neoadjuvant chemotherapy followed by surgery.
粘蛋白13（MUC13）和粘蛋白20（MUC20）是上皮细胞分泌的高分子量跨膜O-连接糖蛋白，在上皮肿瘤细胞中广泛过表达。此前，有报道称MUC13和MUC20是某些上皮肿瘤的预后分子生物标志物，但很少有人研究MUC13或MUC20表达与食管鳞状细胞癌（ESCC）患者预后之间的关系。因此，我们研究的目的是探讨这个问题。
采用免疫组织化学法检测186例接受新辅助化疗后手术的ESCC患者中MUC13和MUC20的表达。我们分析了MUC13或MUC20表达与这些患者长期生存之间的相关性。
MUC13和MUC20在ESCC中的表达主要位于细胞质中。在186名受试者中，53.8%的人MUC13高表达，38.2%的人MUC20高表达。单因素分析显示，MUC13和MUC20均与长期生存无显著相关性。当将MUC13与MUC20的表达相结合时，我们发现MUC13低表达/MUC20高表达患者的中位生存时间明显短于MUC13高表达/MUC20低表达患者（27.7个月对59.5个月，P = 0.021）。多因素分析显示，MUC13/MUC20表达组合是一个独立的预后因素（风险比 = 0.531，95%置信区间：0.299 - 0.944，P = 0.031）。
MUC13/MUC20表达组合是接受新辅助化疗后手术的ESCC患者的潜在预后标志物。
